Traws Pharma Sets Dec 3 Vote on 1-for-8 to 1-for-15 Reverse Split to Save Nasdaq Listing
TRAW is trading near its 52-week low of $0.36 (4.6% above the low) on light trading volume (0.2× avg).
Summary
Traws Pharma's definitive proxy asks shareholders on December 3, 2026 to authorize a reverse split of 1-for-8 to 1-for-15, with the exact ratio left to the board, to lift the share price above Nasdaq's $1.00 minimum before the January 25, 2027 compliance deadline.
Key Events · Corporate Governance and Compliance · TRAW
-
Reverse Split Vote Set for December 3
At the special meeting on December 3, 2026, holders are asked to grant the board authority to split the stock at any ratio from 1-for-8 to 1-for-15, exercisable within 12 months of approval without a further shareholder vote.
-
Nasdaq Deadline January 25, 2027
The company received a bid-price deficiency letter on July 29, 2026 and has until January 25, 2027 to trade back above $1.00; a closing bid of $0.10 or less for ten straight days triggers a delisting notice.
-
Split Math on 15.4M Shares
At 1-for-8, 15,368,277 outstanding shares become 1,921,035 and 29,914,595 warrant shares become 3,739,325; at 1-for-15 they become 1,024,552 and 1,994,307. Authorized shares stay at 250 million either way.
-
No Vote Means Possible Delisting
The proxy states that if Proposal 1 fails, the company cannot implement the split and its common stock could be delisted from Nasdaq.
Analysis · TRAW · Life Sciences
This definitive proxy puts a vote on the table that will decide whether Traws can stay on Nasdaq. The stock trades around $0.38 against a $1.00 minimum bid requirement, and the company has until January 25, 2027 to regain compliance; management says it expects to execute the split shortly after approval. If shareholders vote no, the company states its common stock could be delisted. Approval does not itself fix the business — the Q2 10-Q carried a going concern warning and a large warrant overhang — but it buys the listing and the time to address them. The split also leaves authorized shares at 250 million while cutting outstanding shares, so the pool of unissued authorized stock grows relative to the post-split share count, giving the board room to issue equity later.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRAW was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.36 to $3.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.